Key result
This review summarizes current knowledge on chronic allograft rejection (obliterative bronchiolitis) after lung and heart-lung transplantation, including pathophysiology and clinical grading.
This review summarizes current knowledge on chronic allograft rejection (obliterative bronchiolitis) following heart-lung and lung transplantation, including its pathophysiology and clinical grading.
Answers are grounded in this paper and cite their sources.
Synthesizes current knowledge on post-transplant obliterative bronchiolitis for clinicians; leaves open need for prospective trials on prevention.
Lung and heart-lung transplantation are currently recognized as effective treatment for selected patients with end-stage lung or heart-lung disease. Although the survival rates have improved in recent years, long-term survival is still hampered by the development of chronic rejection. Histologically chronic rejection is manifested by obliterative bronchiolitis (OB), a process that leads to airways obstruction, with a gradual decline in pulmonary function tests. Extensive research efforts have attempted to unravel the pathophysiology of OB and identify key cytokines and growth factors involved in the process. Since the histological diagnosis of chronic rejection remains difficult, a clinical grading system has been proposed, determined as bronchiolitis obliterans syndrome (BOS), divided into four and, more recently, five categories, depending on the severity of airflow obstruction. This paper reviews the current knowledge of chronic rejection after heart-lung and lung transplantation.
No takes yet. Share an insight, caveat, or question.
Geert M. Verleden (2001) conducted a review in Chronic allograft rejection (obliterative bronchiolitis). This review summarizes current knowledge on chronic allograft rejection (obliterative bronchiolitis) after lung and heart-lung transplantation, including pathophysiology and clinical grading.
Synapse has enriched 10 related papers. Consider them for comparative context: